10-K: Bionexus Gene Lab Corp. Reports FY2025 Results

Bionexus Gene Lab Corp. filed its annual report for the fiscal year ended December 31, 2025, detailing revenue decline, strategic partnerships, and ongoing governance remediation.

Summary

• Bionexus Gene Lab Corp. reported a decrease in revenue for the fiscal year ended December 31, 2025, primarily due to lower business volume at its Chemrex subsidiary following a management change.
• The company entered into a strategic partnership with Fidelion Diagnostics Pte. Ltd. for the VitaGuard minimal residual disease platform and an equity purchase agreement with ARC Group International Ltd.
• MRNA Scientific, the genomic screening subsidiary, saw a slight revenue increase, partly due to foreign currency translation effects.
• The company is continuing governance remediation efforts at Chemrex, addressing historical control and approval issues.
• Bionexus Gene Lab Corp. also announced a treasury strategy focused on Ethereum (ETH) and a partnership with ML Tech.
• The company experienced a net loss of $2,984,607 for the year, an increase from the previous year's loss of $1,598,342.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the increased net loss, decreased revenue, and identified material weakness in internal controls, despite some strategic positive developments.

Positives

• MRNA Scientific's revenue increased by 18.8% due to foreign currency translation effects.
• Chemrex's gross margin percentage improved from 13.6% to 14.6% due to a different product mix.
• The company successfully remedied its Nasdaq bid price deficiency following a 1-for-10 reverse stock split.
• Entered into a strategic partnership with Fidelion Diagnostics Pte. Ltd. for the VitaGuard MRD platform, expanding into molecular diagnostics and oncology-related screening.
• Secured an equity purchase agreement with ARC Group International Ltd. for up to $500,000,000 over 36 months.
• Announced a treasury strategy focused on Ethereum (ETH) and partnered with ML Tech for optimization.

Negatives

• Consolidated revenue decreased by 21.9% to $7,424,911 in fiscal year 2025 from $9,510,646 in fiscal year 2024.
• Loss from operations increased by 88% to $2,965,065 in fiscal year 2025 from $1,573,702 in fiscal year 2024.
• Net loss attributable to common shareholders increased to $2,984,607 in fiscal year 2025 from $1,598,342 in fiscal year 2024.
• The company identified a material weakness in internal control over financial reporting at its Chemrex subsidiary due to oversight and authorization lapses.
• The company has a limited operating history and has not achieved profitable operations in the last three fiscal years.
• The company has no product liability or disruption insurance coverage.
• The company has not paid any cash dividends and does not anticipate paying any in the foreseeable future.

Risks

• The company is an early commercial-stage company with a limited operating history, making future performance difficult to predict.
• Future growth may require substantial capital, and there is no assurance that additional funds will be available on satisfactory terms.
• The company may be adversely impacted by changes in laws and regulations, including the potential implementation of the Pathology Act in Malaysia.
• Fluctuations in foreign currency exchange rates could materially affect financial results.
• The company faces risks related to cybersecurity and data protection, including potential cyber attacks and data breaches.
• The company's success depends on the commercialization of its services and products, which may experience significant delays or fail.
• The company's operations are subject to risks associated with doing business in Southeast Asia, including political and economic uncertainties.
• The chemical raw material industry is cyclical and sensitive to economic conditions.
• The company has oral contracts with suppliers and customers, which are generally terminable upon notice.
• The company may be unable to protect its intellectual property adequately.
• The company may pursue collaborations or strategic investments that fail to produce anticipated benefits.

Future Outlook

The company anticipates full remediation of internal control deficiencies, continued development of the VitaGuard MRD platform, expansion into digital healthcare markets, and potential revenue acceleration through strategic alliances, mergers, or acquisitions.

Management Comments

• Managements principal areas of focus during fiscal year 2025 included liquidity management, remediation of internal control and governance issues identified at Chemrex, support for ongoing subsidiary operations, and the evaluation of strategic opportunities in diagnostics-related businesses.
• The Company's ability to continue as a going concern is dependent upon improving its profitability and the ability secure external financing and fundraising.
• Management believes the external financing or fundraising will provide additional cash to meet the Company's obligations as they become due.

Industry Context

StockSavvy.ai notes that Bionexus Gene Lab Corp. operates in two distinct sectors: chemical raw material distribution and genomic screening services. The chemical distribution segment faces cyclicality and competition based on price and availability, while the genomic screening segment is in a rapidly evolving field with potential for growth but also significant competition and regulatory hurdles. The company's recent strategic moves, including the Fidelion partnership, indicate an effort to capitalize on advancements in molecular diagnostics.

Comparison to Industry Standards

• The chemical raw materials market is projected to reach $40.2 billion globally by 2025, with a CAGR of 3.3%, driven by demand for lightweight materials in aerospace, defense, and automotive industries.
• The composites end-user market is expected to reach $114.7 billion globally by 2025.
• The company's genomic screening services operate in a competitive landscape with established diagnostic laboratories and molecular testing providers, where success hinges on scientific validity, clinical acceptance, turnaround time, cost, and reimbursement.

Corporate Governance

Legal Proceedings

• The company is reviewing certain historical transactions involving former officers of Chemrex Corporation Sdn. Bhd. and related governance and approval matters. The review is ongoing, and the company is assessing whether legal actions should be pursued.

Related Party Transactions

• Transactions with Fidelion Diagnostics Pte. Ltd. include other assets of $83,333 and other payables of $83,333 as of December 31, 2025.
• Transactions with Honkuk Material Sdn. Bhd. (affiliated with ex-directors of Chemrex) involved sales and purchases, with factory rental of $4,206 in 2025.
• Transactions with RP Products Sdn. Bhd. (controlled by an ex-director of Chemrex) involved sales of $68,104 and purchases of $9,503 in 2025.
• Amounts owing to directors totaled $49,479 as of December 31, 2025.
• Directors and Ex-Directors Remuneration for 2025 totaled $1,954,831, including salaries and bonuses.

Stakeholder Impact

• Shareholders may experience dilution due to potential future equity financings.
• The material weakness in internal controls could impact investor confidence and access to capital markets.
• The company's ability to continue as a going concern depends on securing external financing, which could affect existing shareholders.
• The strategic partnership with Fidelion and the VitaGuard platform could lead to new revenue streams and potentially benefit shareholders if successful.

Next Steps

• Full remediation of internal control deficiencies and establishment of a uniform group-level risk and compliance framework.
• Continued development of the VitaGuard Minimal Residual Disease (MRD) platform in the South East Asian market.
• Continued expansion into digital healthcare markets, including the deployment of capital into Malaysian government co-investment projects.
• Potential revenue acceleration through strategic alliances, mergers, or acquisitions.
• Review and ratification of affected transactions by the Audit Committee.
• Initiation of an internal audit of Chemrex procurement and contracting procedures.
• Staff retraining on internal control and reporting policies.

Key Dates

Recommendation

While the company is pursuing strategic initiatives like the Fidelion partnership and exploring new treasury assets, the increased net loss, declining revenue, and identified material weakness in internal controls present significant risks. The company's ability to execute its remediation plan and secure future financing without excessive dilution will be critical. Therefore, a 'hold' recommendation is appropriate pending clearer signs of operational improvement and stronger financial performance.

Keywords

Bionexus Gene Lab Corp, 10-K, Annual Report, Chemrex Corporation, MRNA Scientific, Genomic Screening, Chemical Distribution, Fidelion Diagnostics, VitaGuard MRD, Nasdaq, Financial Results, Corporate Governance